Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Generic versions of major hepatitis C drugs are apparently very effective.
Scaling up treatment of hepatitis C among gay and bisexual men in the United Kingdom could in half the number of new cases among that populati...
Non-alcoholic steatohepatitis (NASH) is associated with a 50 percent greater risk of death than non-alcoholic fatty liver disease (NAFLD).
People with non-alcoholic steatohepatitis who lose significant body weight are likely to experience improvements in their disease condition.
The diabetes drug Victoza (liraglutide) has apparently eliminated NASH in a significant proportion of those treated in a recent trial.
Knowing your hepatitis C status has no apparent effect on the likelihood of your developing advanced liver fibrosis.
A new immune therapy targeting hepatitis B has shown promise in an animal study.
With a quarter of Americans living with the condition, fatty liver disease is increasingly a cause of liver cancer.
Researchers have identified a new therapy that could help treat liver cancer in a certain subset of people with the disease.
An investigational anti-diabetes drug may be an option for treating NASH and NAFLD.
Various combinations of Sovaldi, Olysio and ribavirin can cure hepatitis C among those with decompensated cirrhosis.
Daclatasvir and Sovaldi, with or without ribavirin, seem likely to lead to relatively good cure rates among people with genotype 3 of hepatiti...
Daclatasvir and Sovaldi, with or without ribavirin, offer near-perfect hepatitis C cure rates among those who have received a liver transplant...
People with hepatitis C are at increased risk of cardiovascular disease.
A significant proportion of people with undiagnosed hepatitis C likely have advanced liver disease and are in relatively urgent need of treatm...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.